Associations between a Polymorphism in the Pleiotropic GCKR and Age-Related Phenotypes: The HALCyon Programme

Tamuno Alfred1, Yoav Ben-Shlomo1, Rachel Cooper2, Rebecca Hardy2, Ian J. Deary3,4, Jane Elliott5, Sarah E. Harris3,6, Mika Kivimaki7, Meena Kumari7, Chris Power8, John M. Starr3,9, Diana Kuh2, Ian N. M. Day1,10, the HALCyon study team1

1 School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 2 MRC Unit for Lifelong Health and Ageing and Division of Population Health, University College London, London, United Kingdom, 3 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom, 4 Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom, 5 Centre for Longitudinal Studies, Department of Quantitative Social Sciences, Institute of Education, London, United Kingdom, 6 Medical Genetics Section, University of Edinburgh, Edinburgh, United Kingdom, 7 Department of Epidemiology and Public Health, University College London, London, United Kingdom, 8 MRC Centre of Epidemiology for Child Health/Centre for Paediatric Epidemiology and Biostatistics, University College London Institute of Child Health, London, United Kingdom, 9 Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, United Kingdom, 10 MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom

Abstract

Background: The glucokinase regulatory protein encoded by GCKR plays an important role in glucose metabolism and a single nucleotide polymorphism (SNP) rs1260326 (P446L) in the gene has been associated with several age-related biomarkers, including triglycerides, glucose, insulin and apolipoproteins. However, associations between SNPs in the gene and other ageing phenotypes such as cognitive and physical capability have not been reported.

Methods: As part of the Healthy Ageing across the Life Course (HALCyon) collaborative research programme, men and women from five UK cohorts aged between 44 and 90+ years were genotyped for rs1260326. Meta-analysis was used to pool within-study genotypic associations between the SNP and several age-related phenotypes, including body mass index (BMI), blood lipid levels, lung function, and cognitive and physical capability.

Results: We confirm the associations between the minor allele of the SNP and higher triglycerides and lower glucose levels. We also observed a triglyceride-independent association between the minor allele and lower BMI (pooled beta on z-score = −0.04, p-value = 0.0001, n = 16,251). Furthermore, there was some evidence for gene-environment interactions, including physical activity attenuating the effects on triglycerides. However, no associations were observed with measures of cognitive and physical capability.

Conclusion: Findings from middle-aged to older adults confirm associations between rs1260326 GCKR and triglycerides and glucose, suggest possible gene-environment interactions, but do not provide evidence that its relevance extends to cognitive and physical capability.

Citation: Alfred T, Ben-Shlomo Y, Cooper R, Hardy R, Deary IJ, et al. (2013) Associations between a Polymorphism in the Pleiotropic GCKR and Age-Related Phenotypes: The HALCyon Programme. PLoS ONE 8(7): e70045. doi:10.1371/journal.pone.0070045

Editor: Nathan A. Ellis, University of Illinois at Chicago, United States of America

Received November 3, 2012; Accepted June 17, 2013; Published July 23, 2013

Copyright: © 2013 Alfred et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: NCDS 1958 British birth cohort; Phenotype measures (blood pressure, etc.) and DNA collection were funded by the MRC (project grant G000934), and creation of immortalized cell lines were funded by Wellcome Trust Grant 068545/2/02. The NCDS cohort is managed by the Centre for Longitudinal Studies, Department of Quantitative Social Sciences, Institute of Education, London, which is funded as an ESRC Resource Centre. The MRC Centre of Epidemiology for Child Health is funded by the MRC. Great Ormond Street Hospital/University College London, Institute of Child Health receives a proportion of funding from the Department of Health’s National Institute of Health Research (Biomedical Research Centres funding). Samples from the English Longitudinal Study of Ageing (ELSA) DNA Repository (EDNAR), received support under a grant (AG176440651) awarded by the National Institute on Ageing (NIA). ELSA was developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected by the National Centre for Social Research. Whitehall II funding: the Medical Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; National Heart Lung and Blood Institute (NHLBI, R01HL36310), United States (US), National Institutes of Health (NIH): National Institute on Aging (NIA); National Centre for Social Research. Whitehall II funding: the Medical Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; National Heart Lung and Blood Institute (NHLBI, R01HL36310), United States (US), National Institutes of Health (NIH): National Institute on Aging (NIA), R01AG03196 and R01AG034454, US, NIH; Agency for Health Care Policy Research (HS06516); and the John D and Catherine T MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. The Biotechnology and Biological Sciences Research Council (BBSRC) funded the phenotypic data collection and DNA preparation (project grant BB/F019394/1). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (Centre grant G0700704/84698). Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and Medical Research Council (MRC) is gratefully acknowledged. The MRC NSHD is funded by the UK Medical Research Council. RC receives support from the HALCyon programme funded by the New Dynamics of Ageing (RES-353-25-0001). DK and RH are supported by the UK Medical Research Council. M. Kivimaki is supported by the UK MRC, NHLBI. NIA, NIH US and the Academy of Finland. M. Kumari is supported by NHLBI, NIH (HL36310). TA is an ESRC PhD student. HALCyon is funded by the New Dynamics of Ageing across research programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Introduction

The ageing process is complex, comprising several mechanisms and resulting in increased frailty and disease susceptibility [1]. Despite there being no single dominant mechanism of ageing, there are several reported associations observed among age-related phenotypes [2–5], suggesting phenotypes may directly or indirectly affect others and/or that distinct phenotypes may be affected by common causes [6]. For instance, associations observed between cognitive and physical performance in older adults [2,4] may be indicative of genetic factors influencing age-related diseases that lead to the impairment of both sets of indicators or of direct genetic effects on the indicators [6]. Whilst not all studies [7] support a common cause hypothesis for ageing phenotypes [8,9], there are some genes that appear to influence multiple age-related traits.

GCKR (glucokinase (hexokinase 4) regulator) is one such gene with potentially pleiotropic effects. Encoding the glucokinase regulatory protein that regulates the activity of glucokinase (GCK), a regulator of glucose, a non-synonymous [10] single nucleotide polymorphism (SNP), rs1260326 (P446L), in the gene appears to be functional, inhibiting GCK activity in the liver [11]. This property has several phenotypic manifestations, with many reports of the T allele of the SNP being associated with increased levels of triglycerides [10,12–14], in addition to increased C-reactive protein (CRP) [15], factor VII [16], apolipoproteins [12,13], albumin [17], creatinine [18], protein C [19] and uric acid [20], as well as lower levels of insulin [21] and fasting glucose [10,22] in candidate gene and genome-wide association studies (GWAS). SNPs in strong linkage disequilibrium with the variant have also been associated with serum calcium [23] and risk of Crohn’s disease [24]. Furthermore, these genotype associations may be environmentally influenced as there is evidence that an intensive lifestyle intervention, including increased physical activity, may reduce the effects of rs1260326 on triglyceride levels [25].

Given the hypothesised relationships between some of these biomarkers and other important age-related phenotypes, such as physical and cognitive performance [5,26], we hypothesised that GCKR may also be relevant to the capacity to undertake the physical and mental tasks of daily living. Indicators of physical capability, including grip strength, decline from mid-life [27] and have been associated with morbidity [20] and mortality [29] rates. The substantial heritability estimates for these indicators [30,31] suggest genetic variants may contribute to their inter-individual variability. Measures of cognitive capability, such as verbal fluency, also have a substantial genetic component [30,32] and show associations with mortality rate; though these associations may be partly explained by lifestyle and socioeconomic factors [33,34]. We conducted analyses on 16,251 participants aged between 44 and 90+ from five UK cohorts as part of the HALCyon research programme (Healthy Ageing across the Life Course; www.halcyon.ac.uk) to investigate associations between rs1260326 (GCKR) and several age-related phenotypes. From this multi-cohort exploratory study we provide further evidence for the well-reported associations between the SNP and triglycerides, investigate several novel associations, including those with lung function, physical and cognitive capability, as well as explore interactions between the SNP and physical activity and sex on these measures.

Methods

Ethics Statement

Informed consent was obtained from all participants. Ethical approval was obtained from the South-east Multi-centre Research Ethics Committee, the North Thames Multi-centre Research Ethics Committee, the Joint UCL/UCLH Committees on the Ethics of Human Research (Committee Alpha), the Medical Research and Ethics Committee, and the Lothian Research Ethics Committee.

Study Populations

The National Child Development Study (NCDS) follows individuals from all births in England, Scotland and Wales during 1 week in March 1958. In 2002–04 a Biomedical Survey was conducted during home visits by a research nurse. Following informed consent, DNA was extracted from 8017 participants aged 44–45 years; the sample with immortalised cell line culture (n = 7526) is used here. In 2008–09, an eighth sweep was carried out during which cognitive performance tests were conducted [35]. Further details of the study are available on the cohort’s genetic information website (http://www.b38.evegene.ssgul.ac.uk/) and elsewhere [36].

The Medical Research Council National Survey of Health and Development (NSHD) comprises participants sampled from all births in a week in March 1946 and followed up since. In 1999, at age 53 years, men and women were visited by a research nurse and consent for DNA extraction was given by approximately 2900 members of the cohort. Details of the data collected and the several phases of the study are available on the cohort’s website (www.nshd.mrc.ac.uk) and elsewhere [37].

The Whitehall II study targeted all civil servants aged between 35 and 55 years working in London in 1985–88. In 2002–04 (Phase 7), the genetics study was established and DNA was extracted from 6156 participants. Details of the study design and data collected have been described elsewhere [38].

The English Longitudinal Study of Ageing (ELSA) comprises men and women aged 50 years and over who originally participated in the Health Survey for England in 1998, 1999 or 2001. Fieldwork began in 2002–03 (Phase I) with two-yearly follow-ups and in 2004–05 (Phase II) blood samples were provided by 6231 participants. Details of the cohort have been published elsewhere [39].

The Lothian Birth Cohort 1921 (LBC1921) participants were all born in 1921 and most completed a cognitive ability assessment at age 11 years. In 1999–2001 (Wave I), at approximately 79 years old, 550 participants living in and around Edinburgh, underwent a series of cognitive and physical tests. Details of the recruitment into the study are available on its website (www.lothianbirthcohort.ed.ac.uk) and have been published previously [40,41].

Genotyping and Quality Control

Genotype information for GCKR rs1260326 (P446L) came from various sources. In NCDS, information came from both the
illuminar HumanHap550K v3 and Illumina 1.2 M chips (www.illumina.com) [42]. Data in NSHD and Whitehall II came from the Illumina Metabochip. In ELSA, the closest available proxy was used; SNP rs7800994, in very strong linkage disequilibrium ($r^2 = 0.93$; 1000 Genomes Pilot 1, CEU population), was obtained via the Applied Biosystems SNPlex 48-plex SNP genotyping system. Information for LBC1921 came from the Illumina Human 610-Quadv1 Chip [43]. Departure from the Hardy-Weinberg equilibrium was assessed in all studies using the chi-square test.

**Phenotypes**

**Anthropometry and biological function.** Several measures of anthropometry and biological function were used, where available in the cohorts. Body mass index (BMI kg/m$^2$) was calculated as weight divided by height squared derived from measurements conducted at clinics, during a clinical interview in the home, or from self-report. Waist-hip ratio (WHR) was defined as waist circumference (cm) divided by hip circumference (cm). Sitting systolic blood pressure (SBP), diastolic blood pressure (DBP) (mmHg) and pulse rate (BPM) were recorded at the clinical interview; where more than one measurement was taken the mean values were used in analysis. Spirometry was used to assess lung function: forced vital capacity (FVC) and forced expiratory volume in 1s (FEV) in 1s (L); the highest value was used in the analyses. Blood samples were used to measure fibrinogen (g/L), total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol (mmol/L), triglycerides (mmol/L), fasting glucose (mmol/L) and non-fasting glycosylated hemoglobin (HbA1c, %).

**Cognitive capability.** A number of cognitive performance tests in the different studies were used to assess cognitive capability. Different assessments of verbal memory were conducted: in ELSA and NCDS, a list of 10 common words were used, with participants asked to recall the list immediately and again after a delay, the mean score was used in the analysis; in NSHD, 15 words were used over three trials; in Whitehall II 20 words were used; responses in NSHD and Whitehall II were given in writing. In Whitehall II, participants recalled in writing in 1 min as many words as possible beginning with 'S' to assess phonemic fluency, while in LBC1921 three letters 'C', 'F' and 'L' were used with responses given orally. Participants were asked to recall as many animals as possible within 1 min to measure semantic fluency; responses were given orally in ELSA, NCDS and NSHD, and in writing in Whitehall II. To assess search speed [44], 1-min letter searches among grids of letters were used; 600 letters in NSHD and 780 in ELSA and NCDS.

**Physical capability and activity.** Grip strength was measured in NSHD, ELSA and LBC1921 using electronic or hydraulic dynamometers, with the best measure used in the analysis where more than one trial was conducted. Speeds were calculated from timed walks over 2.44 m (8 feet) and 6 m carried out in ELSA and LBC1921 respectively, with the fastest speed used in the analysis where more than one trial was conducted. Timed chair rises [45] involved asking participants to rise from a chair and sit back down 5 times in ELSA and 10 times in NSHD; the reciprocal of time taken in seconds $\times 100$ [46] was used in the analysis. Standing balance tests were conducted with participants’ eyes open using the Flamingo Balance Test [47] (stopped at 30 s) in NSHD and the side-by-side, semi-tandem and full tandem [48] in ELSA. Poor standing balance was defined for this analysis as the inability to complete 5 s. Further details of these measurements in these cohorts are presented elsewhere [49]. Levels of physical activity were derived from self-reported levels using questionnaires. Individuals were categorised as ‘physically active’ in this analysis if they engaged in at least moderate sport or activities at least monthly in NCDS, NSHD and LBC1921, or vigorous sport or activities at least monthly in ELSA or at least weekly in Whitehall II.

**Statistical Methods**

Where information on ethnicity was collected, non-European participants were excluded from analyses in order to avoid confounding from population stratification [50]. Within studies, linear and logistic regression analyses were conducted on the continuous and dichotomous traits within the cohorts respectively, adjusting for age in the age heterogeneous cohorts of ELSA and Whitehall II, as well as sex. Given the strong associations with triglycerides [12,13], in a second model, measures were additionally adjusted for it, as well as height and weight, except when testing for the associations with height, weight, BMI and triglycerides. Additive models were used with genotypes coded as 0, 1 and 2 for the number of minor alleles. Likelihood ratio tests were used to compare the fit of the additive models compared with the full genotype models. For continuous traits, the normality of the standardised residuals was inspected with distributional diagnostic plots. For the harmonisation of continuous traits that were used to obtain pooled estimates of the genotypic effects, z-score units were calculated in each study by subtracting the study mean and dividing by its standard deviation. The overall mean for z-scores is 0 and standard deviation 1. Two-step [51] meta-analyses using a random-effects model were performed to obtain pooled genetic effects. The $\chi^2$ measure was used to quantify heterogeneity [52]. Additionally, meta-analyses of the interaction terms in the second model between the SNP and physical activity, as well as between the SNP and sex were conducted for all outcome measures. Reporting of the analyses met the appropriate items of recommended checklists [53,54]. A two-tailed significance level of $p<0.05$ was used as evidence of statistical significance. Statistical analysis was performed in Stata 11.2 (StataCorp LP). Quanto [55] was used for power calculations using the overall minor allele frequency (MAF) of 0.39.

**Results**

**Cohort Summaries and Genotyping Quality**

Of the 17,004 participants with valid genotypic data, 753 (4.4%) were excluded due to missing values of height, weight and triglycerides, leaving 16,251, as presented in Table 1. Similar genotypic frequencies were observed across the studies and the HWE condition was met for both sources of the NCDS data, as well as for all other studies ($p$-values $> 0.07$), except NSHD ($p$-value $= 0.03$).

**Associations between Genotype and Phenotypes**

Results of the investigations between the SNP and measures of anthropometry and biological function are presented in Table 2 and Table S1. Evidence of associations in the pooled analyses between the SNP and measures of anthropometry were only observed after adjusting for triglycerides, with the T allele being associated with lower weight and BMI (Figure S1). The T allele was also associated with lower WHR after adjusting for age, sex and triglycerides ($p$-value $= 0.002$; data not shown), though this association no longer remained after additional adjustment for height and weight (Table 2). There was no evidence for associations between the GCKR genotype and measures of blood pressure or pulse rate from the pooled results of either model ($p$-values $> 0.02$; Table 2 and Table S1). There was some evidence that the T allele was associated with higher FVC, after additional adjustment for height, weight and triglycerides (Table 2, Table S1,
Table 1. Summary of Sex, Age and GCKR Genotype Frequencies by Cohort.

| Cohort         | Male (%) | Age* in years, median (range) | C/C n (%) | C/T n (%) | T/T n (%) | Total |
|----------------|----------|-------------------------------|-----------|-----------|-----------|-------|
| NCDS           | 50       | 44                            | 1901 (36.4)| 2513 (48.1)| 808 (15.5)| 5222  |
| NSHD           | 47       | 53                            | 819 (35.8)| 1141 (49.8)| 329 (14.4)| 2289  |
| Whitehall II   | 77       | 59 (50–73)                    | 1110 (35.3)| 1535 (48.8)| 502 (16.0)| 3147  |
| ELSA*          | 46       | 64 (52–90+)                   | 1922 (37.7)| 2438 (47.8)| 736 (14.4)| 5096  |
| LBC1921        | 42       | 79 (77–80)                    | 195 (39.2) | 230 (46.3) | 72 (14.5) | 497   |
| Total          | 54       | 53 (44–90+)                   | 5947 (36.6)| 7857 (48.3)| 2447 (15.1)| 16251 |

*Age at phase from which the majority of variables are taken, i.e. ELSA: II; LBC1921: I; NCDS: Biomedical Survey (2002); NSHD: 1999 Collection; Whitehall II: VII. ELSA: English Longitudinal Study of Ageing; NCDS: National Child Development Study; NSHD: National Survey of Health and Development.

Table 2. Anthropometry and Biological Function by GCKR Genotype (Pooled Results).

| Variable                  | Model 1* | Model 2** |
|---------------------------|----------|-----------|
|                           | Beta (95% CI) | p       | t² Het p | Beta (95% CI) | p       | t² Het p |
| Height, cm                | -0.011 (0.030–0.007) | 0.23 | 24.6; 0.26 | 0.006 (0.011–0.023) | 0.48 | 23.7; 0.26 |
| Weight, kg                | -0.018 (0.047–0.011) | 0.23 | 45.1; 0.12 | -0.040 (0.061–0.020) | 0.0001 | 15.9; 0.31 |
| BMI, kg/m²                | -0.011 (0.041–0.019) | 0.48 | 37.1; 0.17 | -0.045 (0.067–0.022) | 0.0001 | 7.4; 0.36 |
| Waist-hip ratio           | 0.006 (0.011–0.022) | 0.51 | 0.0; 0.51 | -0.010 (0.024–0.004) | 0.15 | 0.0; 0.77 |
| Systolic blood pressure, mmHg | 0.007 (0.027–0.041) | 0.67 | 51.9; 0.08 | -0.002 (0.035–0.032) | 0.92 | 52.8; 0.08 |
| Diastolic blood pressure, mmHg | 0.003 (0.035–0.042) | 0.87 | 61.3; 0.035 | -0.003 (0.041–0.036) | 0.90 | 63.6; 0.027 |
| Pulse rate, BPM           | -0.003 (0.028–0.022) | 0.80 | 0.0; 0.55 | -0.015 (0.039–0.010) | 0.24 | 0.0; 0.42 |
| Forced vital capacity, L  | 0.013 (0.006–0.032) | 0.19 | 0.0; 0.64 | 0.022 (0.005–0.039) | 0.013 | 0.0; 0.49 |
| Forced expiratory volume, L | 0.019 (0.012–0.051) | 0.23 | 51.5; 0.10 | 0.030 (0.005–0.065) | 0.09 | 65.0; 0.036 |
| Fibrinogen, g/L           | 0.020 (0.011–0.050) | 0.21 | 30.9; 0.23 | 0.019 (0.008–0.046) | 0.16 | 15.7; 0.31 |
| Total cholesterol, mmol/L | 0.052 (0.019–0.084) | 0.0018 | 47.6; 0.11 | 0.013 (0.018–0.045) | 0.41 | 51.2; 0.08 |
| HDL cholesterol, mmol/L   | 0.000 (0.037–0.037) | 0.98 | 64.3; 0.038 | 0.042 (0.003–0.081) | 0.033 | 75.0; 0.007 |
| Log triglycerides, mmol/L | 0.105 (0.064–0.147) | 6.2×10⁻⁷ | 67.4; 0.015 | 0.112 (0.079–0.145) | 2.8×10⁻¹ | 54.9; 0.064 |
| LDL cholesterol, mmol/L   | -0.004 (0.027–0.019) | 0.75 | 0.0; 0.73 | -0.018 (0.041–0.005) | 0.12 | 0.0; 0.90 |
| Glucose*                  | -0.042 (0.066–0.018) | 0.0007 | 0.0; 0.60 | -0.056 (0.080–0.033) | 2.6×10⁻⁶ | 0.0; 0.74 |

Het- heterogeneity. Beta coefficients per T allele based on z-scores.

*Adjusted for age and sex.

**Additional adjustments: i) height model: weight and triglycerides; ii) weight model: height and triglycerides; iii) triglycerides model: height and weight; iv) BMI model: triglycerides; v) all other models: height, weight and triglycerides.

*Glucose in mmol/L or HbA1c in %.

doi:10.1371/journal.pone.0070045.t002
### Table 3. Cognitive Capability by Cohort and GCKR Genotype.

| Variable                      | Cohort          | Mean (SD) [n] | Model 1* Beta (95% CI) p | I²% Het p | Model 2** Beta (95% CI) p | I²% Het p |
|-------------------------------|-----------------|---------------|--------------------------|-----------|--------------------------|-----------|
| Word recall- 10 words NCDS    | 6.0 (1.5) [5159]| 0.00 (--0.04--0.04) 0.85 | | 0.01 (--0.03--0.04) 0.79 | | |
| Word recall- 45 words NSHD    | 23.9 (6.3) [2235] | 0.05 (--0.01--0.12) 0.08 | | 0.07 (0.01--0.13) 0.0324 | | |
| Word recall- 20 words Whitehall II | 7.0 (2.4) [3103] | 0.03 (--0.08--0.02) 0.25 | | 0.02 (--0.07--0.02) 0.33 | | |
| Word recall- 10 words ELSA    | 5.0 (1.7) [5044] | 0.02 (--0.02--0.06) 0.31 | | 0.03 (--0.01--0.06) 0.16 | | |
| Pooled [15541]                | 0.010 (--0.019--0.038) 0.50 | 37.6; 0.19 0.016 (--0.016--0.047) 0.33 | 48.5; 0.12 | 0.19 0.016 (--0.016--0.047) 0.33 | 48.5; 0.12 | |
| Phonemic fluency- 1 letter Whitehall II | 16.0 (4.1) [3093] | 0.03 (--0.02--0.08) 0.02 | | 0.04 (--0.01--0.09) 0.11 | | |
| Phonemic fluency- 3 letters LBC1921 | 40.5 (12.1) [494] | 0.01 (--0.12--0.14) 0.84 | | 0.00 (--0.13--0.13) 0.99 | | |
| Pooled [3587]                 | 0.030 (--0.016--0.077) 0.20 | 0.0; 0.78 0.035 (--0.012--0.082) 0.14 | 0.0; 0.56 | 0.0; 0.78 0.035 (--0.012--0.082) 0.14 | 0.0; 0.56 | |
| Semantic fluency NCDS         | 22.5 (6.3) [5189] | 0.01 (--0.05--0.04) 0.67 | | 0.01 (--0.05--0.04) 0.73 | | |
| NSHD                          | 23.7 (6.8) [2275] | 0.00 (--0.06--0.06) 0.96 | | 0.01 (--0.05--0.07) 0.80 | | |
| Whitehall II                  | 16.0 (3.7) [3103] | 0.00 (--0.05--0.05) 0.90 | | 0.01 (--0.04--0.06) 0.63 | | |
| ELSA                          | 20.3 (6.1) [5047] | 0.03 (--0.01--0.07) 0.14 | | 0.03 (--0.00--0.07) 0.08 | | |
| Pooled [12343]                | 0.007 (--0.018--0.033) 0.57 | 0.0; 0.97 0.011 (--0.014--0.036) 0.39 | 0.0; >0.99 | 0.0; 0.97 0.011 (--0.014--0.036) 0.39 | 0.0; >0.99 | |

Het- heterogeneity. Beta coefficients per T allele based on z-scores. NCDS: Sweep 8 (2008).
*Adjusted for age and sex.
**Additionally adjusted for height, weight and triglycerides in all models.

### Table 4. Physical Capability by Cohort and GCKR Genotype.

| Variable          | Cohort          | Mean (SD) [n] | Model 1* Beta (95% CI) p | I²% Het p | Model 2** Beta (95% CI) p | I²% Het p |
|-------------------|-----------------|---------------|--------------------------|-----------|--------------------------|-----------|
| Grip strength, kg | NSHD            | 37.8 (14.4) [2206] | 0.01 (--0.05--0.04) 0.77 | 0.00 (--0.04--0.05) 0.84 | | |
| ELSA              | 32.2 (11.5) [5089] | 0.00 (--0.03--0.05) 0.60 | 0.01 (--0.03--0.05) 0.59 | | |
| LBC1921           | 26.7 (9.1) [497] | 0.06 (--0.14--0.02) 0.16 | 0.06 (--0.14--0.02) 0.14 | | |
| Pooled [7756]     | 0.007 (--0.027--0.014) 0.53 | 0.0; 0.44 0.002 (--0.025--0.021) 0.87 | 11.8; 0.32 | | |
| Timed 2.44 m walk | ELSA            | 0.94 (0.29) [3222] | 0.03 (--0.01--0.08) 0.17 | 0.05 (--0.00--0.09) 0.05 | | |
| Timed 6 m walk    | LBC1921         | 1.41 (0.37) [494] | 0.01 (--0.12--0.13) 0.92 | 0.02 (--0.15--0.10) 0.69 | | |
| Pooled [3716]     | 0.029 (--0.014--0.073) 0.19 | 0.0; 0.69 0.034 (--0.015--0.084) 0.17 | 8.4; 0.30 | | |
| Timed chair rises*| NSHD            | 5.2 (1.7) [2148] | 0.01 (--0.05--0.08) 0.69 | 0.01 (--0.05--0.07) 0.76 | | |
| ELSA              | 9.7 (3.1) [4472] | 0.02 (--0.02--0.06) 0.24 | 0.03 (--0.01--0.07) 0.17 | | |
| Pooled [6620]     | 0.021 (--0.013--0.054) 0.23 | 0.0; 0.77 0.022 (--0.011--0.056) 0.19 | 0.0; 0.64 | | |

Het- heterogeneity. Beta coefficients per T allele based on z-scores.
*Adjusted for age and sex.
**Additionally adjusted for height, weight and triglycerides in all models.

Data within cohorts represent the number (%) of participants unable to balance for at least 5s. Data for pooled row represent the number of participants unable to balance for at least 5s/number of participants who performed the test.

Het- heterogeneity. Beta coefficients per T allele based on z-scores.
*Adjusted for age and sex.
**Additionally adjusted for height, weight and triglycerides in all models.

Reciprocal of time taken in sec × 100.
1Data within cohorts represent the number (%) of participants unable to balance for at least 5s. Data for pooled row represent the number of participants unable to balance for at least 5s/number of participants who performed the test.

doi:10.1371/journal.pone.0070045.t003

doi:10.1371/journal.pone.0070045.t004
evidence that the raising effects of the minor allele on log-transformed triglycerides was larger among the physically inactive individuals by around 0.04 z-score units (pooled p-value for interaction terms = 0.06; Figure S7). Figure S8 shows evidence for different genotypic effects in the two groups on LDL cholesterol (pooled p-value for interaction terms = 0.04), with a negative effect of the minor allele observed in the physically active group when analysed separately (pooled beta for LDL cholesterol z-score = 0.01, p-value = 0.7, n = 7725 in inactive; beta = −0.04, p-value = 0.008, n = 7364 in active; data not shown). There was no evidence that the genotypic effects on the other measures differed by physical activity status (p-values>0.09, data not shown).

Interactions between Genotype and Sex

Figures S9 and S10 show that there is evidence that the effects of the genotype on SBP and DBP differed by sex (pooled p-value for interaction terms = 0.002 and 0.005, respectively), with a lowering effect of the minor allele observed in males but not females when analysed separately (e.g. pooled beta for SBP z-score = −0.04, p-value = 0.01, n = 0431 in males; beta = 0.04, p-value = 0.1, n = 7199 in females; data not shown). There was also evidence for an interaction between the genotype and sex on FEV, fibrinogen and phonemic fluency (pooled p-values for interaction terms = 0.04, 0.01 and 0.01, respectively; Figures S11 to S13), though in neither sex did the effects reach statistical significance.

Discussion

We examined associations between the functional [11] GCKR SNP rs1260326 (P446L) and several age-related phenotypes, including previously investigated cardiometabolic biomarkers as well as novel investigations into other phenotypes including measures of cognitive and physical capability, in 16,251 men and women aged between 44 and 90+ years from five UK cohorts. We confirmed the well-reported associations between the minor (T) allele of the SNP and higher levels of triglycerides and lower levels of glucose. In addition, we observed an association between the allele and lower weight and BMI, as well as higher FVC and HDL, which was only apparent after adjusting for triglycerides. A stronger association with glucose was observed after triglyceride adjustment. Despite the reported associations with a range of biomarkers [12,13,15-20], we found no strong evidence for associations between the SNP and our other age-related phenotypes, including measures of grip strength and verbal memory. Our investigation into interactions between the genotype and self-reported physical activity on our phenotypes provide further evidence for a possible reduction in the genotypic effect on triglycerides in physically active individuals [25], a reduction in triglyceride-adjusted LDL cholesterol in active individuals, as well as evidence for the triglyceride-adjusted effect on weight occurring in physically inactive individuals only. We also found evidence for sex differences in the genotypic effects on SBP and DBP with reduced effects of the T allele only observed in males. These findings may provide insight into the mechanisms of GCKR on various phenotypes and should encourage the continued exploration into the modifiers of the genotypic effects of this and other genes.

GWAS and candidate gene studies have identified SNPs in GCKR that are strongly associated with a range of traits. In particular, there is very strong evidence that the T allele of rs1260326 is associated with increased levels of triglycerides [12,13], CRP [15] and lower glucose [10], however there is disagreement among previous reports regarding the associations for some other phenotypes. For instance, many studies including one conducted in 4363 Europeans [21] found no association between the SNP and BMI and WHR, whereas an investigation into 2900 Han Chinese older adults found an association between the T allele and lower BMI and waist circumference [56] which, unlike in our study, was apparent before adjustment for triglycerides. Furthermore, differences have been reported for SNPs in the gene regarding associations with apolipoprotein B [12,13], LDL [14,57] and HDL cholesterol [14,58]. With respect to the latter, similar to our findings, a positive association with the minor allele of rs780094 (T with rs1260326 is 0.93) and HDL cholesterol was observed only after adjusting for triglycerides in a study of around 10,000 middle-aged adults [59]; suggesting the very strong association with triglycerides may be confounding associations between SNPs in the gene and other traits. Our findings for differential genotypic effects on triglycerides, LDL cholesterol and weight by physical activity status are in line with other reports that suggest that physical activity can modify genetic effects [90,61] and, along with confounding by triglycerides, may provide insight into the contributing factors for the mixed reports for associations of SNPs in GCKR on phenotypes. We also found evidence for an interaction between the GCKR genotype and sex on SBP and DBP, though, a large multi-study investigation comprising over 34,000 individuals of European ancestry found no association between SNP rs780094 and SBP and DBP [58], however, further investigations into these associations by sex are required to determine whether our findings in males are true associations.

To the best of our knowledge, this is the first report of an investigation between SNPs in GCKR and measures of lung function, physical and cognitive capability. The null associations observed for physical and cognitive capability, both before and after adjustment for triglycerides, glucose, and body size, in either sex or physical activity group, from our large multi-cohort study provides evidence against the importance of the gene to ageing beyond cardiometabolic biomarkers and weight. Sample size calculations determined that we were well-powered to detect reasonably small effects on quantitative traits. For example, around 5000 individuals would be required to detect a beta coefficient of 0.06 z-score units with 80% power at the 5% significance level, corresponding to a difference in semantic fluency of around 0.7 points between the two homozygote groups, assuming a standard deviation of 6, or around 1.3 kg in grip strength, assuming a standard deviation of 11. Whilst further larger investigations into the measures of cognitive and physical capability could reveal some associations, our study did not provide evidence for an effect of GCKR rs1260326 on these traits. Therefore, GCKR appears not to be a common cause of ageing from the phenotypes we investigated and, as yet, there appear to be very few examples of genes that independently influence a range of diverse ageing domains.

As adjusting for triglycerides revealed further or stronger associations for the SNP with some traits, the lack of availability of other biomarkers in our study may mean that we have missed the identification of further associations. For example, a triglyceride-independent effect on CRP has been observed [25] and relationships between inflammatory biomarkers of ageing and cognitive capability have been hypothesised [26]. Therefore, further investigations into cognitive and physical capability in studies that can adjust for other biomarkers may be useful.

Conclusion

The results of this large multi-cohort study of middle-aged to older adults confirm associations between the functional GCKR
SNP rs1260326 (P446L) and triglycerides and glucose, suggest an environmentally modifiable effect on triglycerides, LDL and weight, but do not provide evidence for its relevance to other ageing phenotypes, such as grip strength and verbal memory.

Supporting Information

Figure S1 Meta-analysis for the Associations between GCKR Genotype and BMI. Adjusted for age, sex and triglycerides. Coefficients based on z-scores.

Figure S2 Meta-analysis for the Associations between GCKR Genotype and FVC. Adjusted for age, sex, height, weight and triglycerides. Coefficients based on z-scores.

Figure S3 Meta-analysis for the Associations between GCKR Genotype and HDL Cholesterol. Adjusted for age, sex, height, weight and triglycerides. Coefficients based on z-scores.

Figure S4 Meta-analysis for the Associations between GCKR Genotype and Log Triglycerides. Adjusted for age, sex, height and weight. Coefficients based on z-scores.

Figure S5 Meta-analysis for the Associations between GCKR Genotype and Glucose. Adjusted for age, sex, height, weight and triglycerides. Coefficients based on z-scores. HbA1c(%) in NCDS, NSHD and LBC1921; glucose (mmol/L) in Whitehall II and ELSA.

Figure S6 Meta-analysis for the Interaction between GCKR Genotype and Physical Activity on Weight. Adjusted for age, sex, height and triglycerides. Coefficients based on z-scores. Comparing participants defined as physically active to those physical inactive.

Figure S7 Meta-analysis for the Interaction between GCKR Genotype and Physical Activity on Log Triglycerides. Adjusted for age, sex, height and weight. Coefficients based on z-scores. Comparing participants defined as physically active to those physical inactive.

Figure S8 Meta-analysis for the Interaction between GCKR Genotype and Physical Activity on LDL Cholesterol. Adjusted for age, sex, height, weight and triglycerides. Coefficients based on z-scores. Comparing participants defined as physically active to those physical inactive.

Figure S9 Meta-analysis for the Interaction between GCKR Genotype and Sex on Systolic Blood Pressure. Adjusted for age, height, weight and triglycerides. Coefficients based on z-scores. Comparing females to males.

Figure S10 Meta-analysis for the Interaction between GCKR Genotype and Sex on Diastolic Blood Pressure. Adjusted for age, height, weight and triglycerides. Coefficients based on z-scores. Comparing females to males.

Figure S11 Meta-analysis for the Interaction between GCKR Genotype and Sex on FEV. Adjusted for age, height, weight and triglycerides. Coefficients based on z-scores. Comparing females to males.

Figure S12 Meta-analysis for the Interaction between GCKR Genotype and Sex on Fibrinogen. Adjusted for age, height, weight and triglycerides. Coefficients based on z-scores. Comparing females to males.

Figure S13 Meta-analysis for the Interaction between GCKR Genotype and Sex on Phonemic Fluency. Adjusted for age, height, weight and triglycerides. Coefficients based on z-scores. Comparing females to males.

Table S1 Anthropometry and Biological Function by GCKR Genotype (Full Results). Het- heterogeneity. Beta coefficients per T allele based on z-scores. *Adjusted for age and sex. **Additionally adjusted for height, weight and triglycerides in all models, except: i) height-weight and triglycerides, ii) weight-height and triglycerides, iii) triglycerides-height and weight. *Full genotype model representing a significantly better fit than the given per allele model. Whitehall II: fibrinogen from Phase V.

Acknowledgments

We thank Jorgen Engmann, Jon Johnson, Aida Sanchez, Andrew Taylor and Andrew Wong for providing data.

We thank the Lothian Birth Cohort 1921 participants. We thank the Scottish Council for Research in Education for allowing access to the Scottish Mental Survey 1932.

The HALCyon Study team also includes: Paula Aucott, Department of Geography, University of Portsmouth, Portsmouth, United Kingdom; Leone Craig, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; Panayotes Demakakos, Department of Epidemiology and Public Health, University College London, London, UK; Catharine Gale, MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; John Gallacher, Department of Primary Care and Public Health, Cardiff University, Cardiff, UK; Mike Gardner, School of Social and Community Medicine, University of Bristol, Bristol, UK; James Goodwin, Age UK, UK; Carmen Martin-Ruiz, Institute for Ageing and Health, Newcastle University, Newcastle, UK; Geraldine McNell, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; Gita Mishra, School of Population Health, University of Queensland, Herston, Australia; Zeinab Mulla, MRC Unit for Lifelong Health and Ageing and Institute of Epidemiology and Health Care, University College London, London, UK; Emily Murray, MRC Unit for Lifelong Health and Ageing and Institute of Epidemiology and Health Care, University College London, London, UK; Sam Parsons, Centre for Longitudinal Studies, Institute of Education, London, UK; Marcus Richards, MRC Unit for Lifelong Health and Ageing and Institute of Epidemiology and Health Care, University College London, London, UK; Paul Shiel, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Humphrey Southall, Department of Geography, University of Portsmouth, Portsmouth, UK; Alison Stephen, MRC Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, UK; Andrew Steptoe, Department of Epidemiology and Public Health, University College London, London, UK; Kate Tilting, School of Social and Community Medicine, University of Bristol, Bristol, UK; Vicky Tsipouri, MRC Unit for Lifelong Health and Ageing and Institute of Epidemiology and Health Care, University College London, London, UK; Thomas von Zglinicki, Institute for Ageing and Health, Newcastle University, Newcastle, UK; Lawrence Whalley, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.

Author Contributions

Conceived and designed the experiments: INMD YB-S. Analyzed the data: TA. Wrote the paper: TA. Advised on the statistical analyses and contributed to the manuscript: INMD YB-S. Contributed to the HALCyon programme:
References

1. Kirkwood TBL (2008) A systematic look at an old problem. Nature 451: 644–647. doi:10.1038/451644a.

2. Kuh D, Cooper R, Hardy R, Guralnik J, Richards M (2009) Lifetime cognitive performance is associated with midlife physical performance in a prospective national birth cohort study. Psychosom Med 71: 30–40. doi:10.1097/PSY.0b013e3181a82620.

3. Enright PL, McMinnie RA, Bittner V, Tracy RP, McNamara R, et al. (2003) The 6-min walk test: a quick measure of functional status in elderly adults. Chest 123: 387–390.

4. Deary IJ, Whalley LJ, Batty GD, Starr JM (2006) Physical fitness and lifetime cognitive change. Neurology 67: 1195–1200. doi:10.1212/01.wnl.0000238520.06958.6a.

5. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DRW, et al. (2005) Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care 28: 2541–2542.

6. Johnson W, Deary IJ, McGue M, Christensen K (2009) Genetic and environmental links between cognitive and physical functions in old age. J Gerontol B Psychol Sci Soc Sci 64: 63–72. doi:10.1093/geronb/gln033.

7. Mackinnon A, Christensen H, Jorm AF (2006) Search for a common cause factor amongst cognitive, speed and biological variables using narrow age cohorts. Gerontology 52: 245–257. doi:10.1159/000090963.

8. Christensen H, Mackinnon AJ, Korten A, Jorm AF (2001) The “common cause hypothesis” of cognitive aging: evidence for not only a common factor but also specific associations of age with vision and grip strength in a cross-sectional analysis. Psychol Aging 16: 388–399.

9. Borel PR, Lindenberg U (1997) Emergence of a powerful connection between sensory and cognitive functions across the adult life span: a new window to the study of cognitive aging? Psychol Aging 12: 12–21.

10. Orho-Melander M, Melander O, Guiducci C, Peruze-Martinez P, Corrada D, et al. (2008) Common genetic variants in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57: 3112–3121. doi:10.2337/db08-0516.

11. Beer NL, Trible M, McColloch JL, Roos C, Johnson PRV, et al. (2009) The P46H variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18: 4081–4088. doi:10.1093/hmg/ddp537.

12. Varbo A, Beno M, Thybo-Hansen A, Grande P, Nordensgaard BG (2011) TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol 31: 451–457. doi:10.1161/ATVBAHA.110.216333.

13. Kathiresan S, Willer CJ, Peraldo GM, Demissie S, Munar V, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–63. doi:10.1038/ng.291.

14. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma DI, Heid IM, et al. (2009) Loci centric association scan for Coagulation Factor VII levels in European and African-Americans. PLoS Genet 5: e1000504. doi:10.1371/journal.pgen.1000504.

15. Dehghan A, Dupuis J, Batici M, Biscaglia M, Eiriksdottir G, et al. (2011) Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123: 731–738. doi:10.1161/CIRCULATIONAHA.110.948157.

16. Taylor KC, Lange LA, Zabaneh D, Lange E, Keating BJ, et al. (2011) A genetic-centric scan for coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARG) Consortium. Hum Mol Genet 20: 3525–3534. doi:10.1093/hmg/ddr264.

17. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, et al. (2010) Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 42: 210–215. doi:10.1038/ng.531.

18. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376–381. doi:10.1038/ng.568.

19. Tung W, Basu S, Kong X, Pankow JS, Alakne K, et al. (2010) Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. Blood 116: 5032–5036. doi:10.1182/blood-2010-05-283739.

20. Kohl M, Johnson T, Sanna S, Teumer A, Vitart V, et al. (2009) Meta-analysis of 20,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5: e1000504. doi:10.1371/journal.pgen.1000504.

21. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marre M, et al. (2008) The common P46H polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 57: 2253–2257. doi:10.2337/db07-1807.

22. Manning AK, Hivert M-F, Scott RA, Grimsby JL, Boslaugh-Naji N, et al. (2012) A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycermic traits and insulin resistance. Nat Genet 44: 659–669. doi:10.1038/ng.2274.
British men and women: associations with physical activity, health status, and socioeconomic conditions. J Gerontol A Biol Sci Med Sci 60: 224–231.

47. Committee of Experts on Sports Research (1993) Eurofit: handbook for the EUROFIT tests of physical fitness. Strasbourg: Council of Europe. 2nd Edition.

48. Stevens KN, Lang IA, Guralnik JM, Melzer D (2008) Epidemiology of balance and dizziness in a national population: findings from the English Longitudinal Study of Ageing. Age Ageing 37: 300–305. doi:10.1093/ageing/afn019.

49. Cooper R, Hardy R, Aliie Sayer A, Ben-Shlomo Y, Birnie K, et al. (2011) Age and Gender Differences in Physical Capability Levels from Mid-Life Onwards: The Harmonisation and Meta-Analysis of Data from Eight UK Cohort Studies. PLoS One 6: e27899. doi:10.1371/journal.pone.0027899.

50. Cordell HJ, Clayton DG (2005) Genetic association studies. Lancet 366: 1121–1131. doi:10.1016/S0140-6736(05)67437-7.

51. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340: c221. doi:10.1136/bmj.c221.

52. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560. doi:10.1136/bmj.327.7414.557.

53. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA 283: 2008–2012. doi:10.1001/jama.283.15.2008.

54. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, et al. (2009) Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol 62: 597–608.e4. doi:10.1016/j.jclinepi.2008.12.004.